Maxygen to Present at the 2007 UBS Global Life Sciences Conference
A live webcast of the presentation can be accessed on Maxygen's website athttp://www.maxygen.com/webcasts. A replay of the presentation will beavailable starting at approximately 3:00 p.m. Eastern Time on September 25,and will be available until October 27, 2007.
Maxygen is a biopharmaceutical company focused on developing improvedversions of protein drugs. We look for opportunities where our proprietaryprotein modification technologies can address significant therapeutic needs.Products developed by Maxygen now in clinical trials include a novelinterferon-alpha for the treatment of hepatitis C virus (HCV) infection and anovel G-CSF for the treatment of neutropenia. Maxygen's approach may allow usto leverage the established development and regulatory paths of approveddrugs. We believe this advantage translates to a greater chance ofsuccessfully bringing important new drugs to market. http://www.maxygen.com
SOURCE Maxygen, Inc.
You May Also Like